Cellectar Biosciences (CLRB) Projected to Post Earnings on Tuesday

Cellectar Biosciences (NASDAQ:CLRB) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect Cellectar Biosciences to post earnings of ($0.17) per share for the quarter.

Cellectar Biosciences Stock Performance

CLRB opened at $0.25 on Monday. Cellectar Biosciences has a 52-week low of $0.22 and a 52-week high of $3.49. The stock has a market capitalization of $11.40 million, a PE ratio of -0.14 and a beta of 0.48. The stock’s 50 day moving average price is $0.30 and its 200-day moving average price is $0.63.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Cellectar Biosciences in a report on Monday, May 5th. They issued a “sell” rating for the company.

Institutional Trading of Cellectar Biosciences

An institutional investor recently raised its position in Cellectar Biosciences stock. Bank of America Corp DE lifted its holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 25.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 206,783 shares of the biopharmaceutical company’s stock after buying an additional 41,704 shares during the quarter. Bank of America Corp DE owned approximately 0.45% of Cellectar Biosciences worth $62,000 as of its most recent SEC filing. Institutional investors and hedge funds own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.